Reimbursement Prices Higher In Japan Than Overseas

16 January 1995

Drug prices in Japan are high and drug efficacy evaluations are often too lenient, with drugs with a low international evaluation assigned very high prices, according to a study by Rokuro Hama of Japan's Department of Internal Medicine, Hannan Central Hospital, Osaka, reported in Pharma Japan. The study was on the 49 leading products in Japan, comparing these with the UK, France, the USA and Germany.

The simple average reimbursement price ratios were 3.09 for Japan vs the UK, 2.65 vs France, 1.53 vs the USA and 1.70 vs Germany. Among individual drugs, the price of the antiallergy agent terfenadine was 11 times that in the UK and 4.8 times that in France, while for ketotifen the price was 5.8 times that in the UK and 6.4 times that in France.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.